{"doi":"10.1049/nbt2.12145","title":"PLGA‐PEG‐c(RGDfK)‐ <i>Kushenol</i> E micelles (PPCKM) with a therapeutic potential for targeting ovarian cancer","abstract":"Abstract Diagnosis of ovarian cancer is often carried out at late‐stage, thus requiring more effective treatment strategies. Kushenol E (KE) as a poorly soluble drug exhibits strong antiproliferative activity in cancer cells but no related studies have reported in anti‐ovarian cancer. It is very beneficial to enhance antineoplastic properties of KE to establish an ovarian tumor‐targeting nanoparticle system modified with tumor‐homing c(RGDfK) peptides. In the current study, PLGA‐PEG‐c(RGDfK)‐KE micelles (PPCKM) were prepared to overcome poor water solubility of KE to meet the requirement of tumor active targeting. The PPCKM showed a higher drug cumulative release ratio (82.16 ± 7.69 % vs 34.96 ± 3.05 %, at 1.5 h) with good morphology, particle size (93.41 ± 2.84 nm), and entrapment efficiency (89.7% ± 1.3%). The cell viability, migration and apoptosis analysis of SKOV‐3 cells demonstrated that PPCKM retained potent anti‐tumor effects, and promoted apoptosis at early and advanced stage with concentration‐dependent. Based on establishment of xenograft models in BALB/c nude mice, we discovered that PPCKM reduced tumor volume and weight, inhibited PCNA and Ki67 expression, as well as promoted apoptosis by targeting the tumor site. Collectively, these findings suggest that PPCKM may serve as an effective therapeutic option for ovarian cancer. This article is protected by copyright. All rights reserved.","journal":"IET Nanobiotechnology","year":2025,"id":585063,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9534,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1498474,"name":"Lijuan Lu","orcid":"0000-0002-8465-1024","position":1,"is_corresponding":false},{"id":1498475,"name":"Juan Ren","orcid":"0000-0003-0184-2157","position":2,"is_corresponding":false},{"id":1487392,"name":"Ran Li","orcid":"0000-0003-2794-9948","position":3,"is_corresponding":false},{"id":1498476,"name":"Bo Sun","orcid":"0000-0002-5343-9178","position":4,"is_corresponding":false},{"id":1498894,"name":"Haopeng Wan","orcid":null,"position":5,"is_corresponding":false},{"id":1267529,"name":"Xue Chen","orcid":"0000-0002-1282-3405","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:59:20.067334Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}